Latest Conference Articles

In this interview, Chalmers highlights the implications of his team’s subgroup analysis findings in the ASPEN trial, as well as unmet needs for non-cystic fibrosis bronchiectasis.

Findings from a post hoc analysis of the phase 3 DIRECTION study highlight tezepelumab’s consistent benefit on asthma exacerbations across trigger categories.

Trief and MD candidate Justin Cheong physically peeled the Haab’s striae from a patient’s eye, allowing for better adherence and maintenance of the DSEK graft.

At ATS 2025, these data highlight a potential connection between asthma development and prenatal exposure to microplastics and other forms of pollution.

Murphy discusses innovative surgical techniques for managing glaucoma and cataracts, emphasizing minimally invasive approaches and the future of ophthalmology.

This interview highlights the subgroup analysis findings of the ASPEN trial, specifically on brensocatib for non-cystic fibrosis bronchiectasis.

This special episode of Lungcast features Harold P. Wimmer, CEO of the ALA, and Francesca Polverino, MD, PhD, an ALA spokesperson.

Gerard Criner, MD, reviews findings from a secondary analysis of the phase 3 MATINEE trial of mepolizumab and looks ahead to the potential significance of the drug, if approved.

In her interview at ATS, Willen further described elements highlighted in her presentation on new treatments for sickle cell disease.

Breazzano presented a video of a surgery repositioning an Akreos AO60 lens, highlighting the complicated nature of the procedure and its planning.

Abramson discusses the potential benefits and limitations of treatment methods for Coats’ disease and further discusses the genetic component of its pathology.

This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.

Criner reviews findings from AIRFLOW-3 and describes the subgroup of targeted lung denervation treatment responders being targeted in AIRFLOW-4.

Results highlight dupilumab’s real-world benefit for asthma control in patients with and without coexisting chronic rhinosinusitis and/or nasal polyposis.

At ATS 2025, these post-hoc analysis findings on taladegib (ENV-101) highlight the treatment’s efficacy for idiopathic pulmonary fibrosis.

Attaway describes the importance of screening for and treating sarcopenia in patients with COPD and clinical gaps that complicate this process.

In this interview at ATS 2025, Arthur Reingold, MD, highlights the role of pulmonologists and other health care providers in combatting vaccine misinformation.

Marchetti explains the benefits of assessing RV/TLC rather than absolute RV to determine the efficacy of BLVR in patients with emphysema and hyperinflation.

This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.

Abramson's presented operation indicates that Coats disease can manifest bilaterally and is potentially caused by multiple independent genes.

Williams discusses her takeaways from the 2025 Envision conference and her expectations for the future of both ophthalmology and its practitioners.

This interview at ATS 2025 highlights the talk given by Grace Lee, MD, MPH, regarding the policy side of public health concerns over widespread immunization.

A post-hoc analysis of SURMOUNT-OSA highlights tirzepatide’s consistent benefit across all baseline OSA severity groups.

The FIBRONEER-IPF and FIBRONEER-ILD data highlight nerandomilast’s efficacy and safety in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.

The pooled analysis of ENHANCE clinical trial program data highlight improvements in HRQoL, dyspnea, and COPD symptoms with ensifentrine monotherapy.

Nearly all treated patients received glucocorticoids, but many quickly needed later-line therapies, especially those with non-incident pulmonary sarcoidosis.

The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.